Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin, Natamycin and Others}, Allylamines {Butenafine, Terbinafine and Naftifine}, and Others], Infection Type [Superficial Antifungal Infection and Systemic Antifungal Infection], Dosage form [Drugs, Ointment, Powder and Others] and Therapeutic Indication [Aspergillosis, Dermatophytosis, Candidiasis, and Others] - Global Opportunity Analysis and Industry Forecast, 2017-2023
Antifungal drugs are used to treat fungal infections, which occur due to unclean, humid, and unhygienic environments. These infections are caused by organisms, which live by feeding on living tissue and are commonly known as dermatophytes that are responsible for the infection of hair, skin and nail as they can utilize keratin. In addition, fungal infections can cause harm to superficial (skin, mouth, and vagina) and systemic parts of the body (lungs, bones, brain, eyes, and others) Some of the common fungal infections such as athlete’s foot, fungal meningitis, ringworm and other infections can be treated by antifungal drugs that work by killing of the fungal cell breaking the contents of the cell. These cells eventually leak out and results in the death of the cell, which also prevents the cell to grow further, thus preventing the infection. The global antifungal drugs market was valued at $13,719 million in 2016, and is expected to reach at $17,718 million by 2023, registering a CAGR of 3.7% from 2017 to 2023.
There are various modes of anti-fungal drug delivery that increases adoption of this products leading to high growth of this market. In addition, absorption of drugs works differently for each individual. Hence, advancement in drug delivery technology is expected to boost the growth of the global antifungal drug market. Further, growing incidence and prevalence rate of infectious diseases and growth in population of immunocompromised (prone to infectious diseases) individuals enhance the growth of this market. Furthermore, presence of alternative therapies and slow growth of medical infrastructure in emerging economies, such as China and India, hinder the market growth during the forecast period.
The global antifungal drugs market is segmented based on drug type, therapeutic indications, infection type, and geography. Based on drug type, the market is divided into echinocandins, azoles, polyenes, allylamines, and other drugs. Further, based on therapeutic indications, it is classified into aspergillosis, dermatophytosis, candidiasis, others. Based on infection type, the market is bifurcated into superficial and systemic antifungals.
Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2016, and is expected to maintain the dominance throughout the forecast period. This is attributed to the increase in prevalence of fungal infections and growth in development of antifungal biopharmaceuticals, However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, due to the improvement in healthcare facilities, available disposable income, and rapid development of economic conditions.
KEY MARKET BENEFITS
By Drug Type
There are various modes of anti-fungal drug delivery that increases adoption of this products leading to high growth of this market. In addition, absorption of drugs works differently for each individual. Hence, advancement in drug delivery technology is expected to boost the growth of the global antifungal drug market. Further, growing incidence and prevalence rate of infectious diseases and growth in population of immunocompromised (prone to infectious diseases) individuals enhance the growth of this market. Furthermore, presence of alternative therapies and slow growth of medical infrastructure in emerging economies, such as China and India, hinder the market growth during the forecast period.
The global antifungal drugs market is segmented based on drug type, therapeutic indications, infection type, and geography. Based on drug type, the market is divided into echinocandins, azoles, polyenes, allylamines, and other drugs. Further, based on therapeutic indications, it is classified into aspergillosis, dermatophytosis, candidiasis, others. Based on infection type, the market is bifurcated into superficial and systemic antifungals.
Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2016, and is expected to maintain the dominance throughout the forecast period. This is attributed to the increase in prevalence of fungal infections and growth in development of antifungal biopharmaceuticals, However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, due to the improvement in healthcare facilities, available disposable income, and rapid development of economic conditions.
KEY MARKET BENEFITS
- The study provides an in-depth analysis of the global antifungal drugs market, with current trends and future estimations to elucidate the imminent investment pockets.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Comprehensive quantitative analysis of the industry from 2016 to 2023 is provided to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry, which helps understand the type of products and technologies used globally, is also included.
- Key market players and their strategies are provided to understand the competitive outlook of the market.
By Drug Type
- Echinocandins
- Caspofungin
- Micafungin
- Anidulafungin
- Others
- Azoles
- Imidazoles
- Voriconazole
- Thiazoles
- Others
- Polyenes
- Amphotericin B
- Candicidin
- Hamycin
- Natamycin
- Others
- Allylamines
- Butenafine
- Terbinafine
- Naftifine
- Others
- Superficial Antifungal Infections
- Systemic Antifungal Infections
- Aspergillosis
- Dermatophytosis
- Candidiasis
- Others
- Powders
- Ointments
- Drugs
- Others
- North America
- U.S.
- Canada
- Mexico
- Europe
- U.K.
- France
- Germany
- Italy
- Spain
- Rest of Europe
- Asia-pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Argentina
- Egypt
- Israel
- South Africa
- Rest of LAMEA
- Pfizer Inc.
- Sanofi S.A.
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- Scynexis Inc.
- Novartis International AG
- Abbott Laboratories
- Bayer AG
- Enzon Pharmaceuticals, Inc.
- GlaxoSmithKline Plc.
- Sigma-Aldrich Corporation
- Agilent Technologies, Inc.
- Beckman Coulter, Inc. (a subsidiary of Danaher Corporation)
- Tecan Group
- Astellas Pharma, Inc.
- Basilea Pharmaceutical Ltd.
- Valeant Pharmaceuticals International, Inc.
- Kramer Laboratories
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.1.1. Increasing prevalence of fungal infection
3.6.1.2. Rising awareness levels pertaining to myriad fungal infections
3.6.1.3. Favorable government funds to combat the antifungal diseases
3.6.2. Restraints
3.6.2.1. Growing population with antifungal drug resistance
3.6.2.2. Presence of counterfeit drugs and side effects of antifungal drugs
3.6.3. Opportunities
3.6.3.1. Patent expirations and increasing funding from public & private organizations
CHAPTER 4 ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. SUPERFICIAL ANTIFUNGAL INFECTION
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. SYSTEMIC ANTIFUNGAL INFECTION
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
CHAPTER 5 ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. ECHINOCANDINS
5.2.1. Market size and forecast
5.2.2. Micafungin
5.2.2.1. Market size and forecast
5.2.3. Caspofungin
5.2.3.1. Market size and forecast
5.2.4. Anidulafungin
5.2.4.1. Market size and forecast
5.2.5. Others
5.2.5.1. Market size and forecast
5.3. AZOLES
5.3.1. Market size and forecast
5.3.1. Imidazoles
5.3.1.1. Market size and forecast
5.3.2. Voricanazole
5.3.2.1. Market size and forecast
5.3.3. Thiazoles
5.3.3.1. Market size and forecast
5.3.4. Others
5.3.4.1. Market size and forecast
5.4. POLYENES
5.4.1. Market size and forecast
5.4.2. Amphotericin B
5.4.2.1. Market size and forecast
5.4.3. Candicidin
5.4.3.1. Market size and forecast
5.4.4. Hamycin
5.4.4.1. Market size and forecast
5.4.5. Natamycin
5.4.5.1. Market size and forecast
5.4.6. Others
5.4.6.1. Market size and forecast
5.5. ALLYLAMINES
5.5.1. Market size and forecast
5.5.1. Terbinafine
5.5.1.1. Market size and forecast
5.5.2. Butenafine
5.5.2.1. Market size and forecast
5.5.3. Naftifine
5.5.3.1. Market size and forecast
5.6. OTHERS
5.6.1. Market size and forecast
CHAPTER 6 ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. ASPERGILLOSIS
6.2.1. Market size and forecast
6.3. DERMATOPHYTOSIS
6.3.1. Market size and forecast
6.4. CANDIDIASIS
6.4.1. Market size and forecast
6.5. OTHERS
6.5.1. Market size and forecast
CHAPTER 7 ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. POWDER
7.2.1. Market size and forecast
7.3. OINTMENTS
7.3.1. Market size and forecast
7.4. DRUGS
7.4.1. Market size and forecast
7.5. OTHERS
7.5.1. Market size and forecast
CHAPTER 8 ANTIFUNGAL DRUGS MARKET, BY GEOGRAPHY
8.1. OVERVIEW
8.1.1. Market size and forecast
8.2. NORTH AMERICA
8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast
8.2.3.1. U.S. market size and forecast
8.2.3.2. Mexico market size and forecast
8.2.3.3. Canada market size and forecast
8.3. EUROPE
8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast
8.3.3.1. UK market size and forecast
8.3.3.2. France market size and forecast
8.3.3.3. Germany market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Spain market size and forecast
8.3.3.6. Rest of Europe market size and forecast
8.4. ASIA-PACIFIC
8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast
8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. India market size and forecast
8.4.3.4. Australia market size and forecast
8.4.3.5. Rest of Asia-Pacific market size and forecast
8.5. LAMEA
8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast
8.5.3.1. Brazil market size and forecast
8.5.3.2. Argentina market size and forecast
8.5.3.3. Saudi Arabia market size and forecast
8.5.3.4. South Africa market size and forecast
8.5.3.5. Rest of LAMEA market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1. PFIZER INC.
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance
9.1.5. Key strategic moves and developments
9.2. SANOFI S.A
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Business performance
9.2.5. Key strategic moves and developments
9.3. GILEAD SCIENCES INC.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Business performance
9.3.5. Key strategic moves and developments
9.4. MERCK & CO., INC.
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance
9.4.5. Key strategic moves and developments
9.5. NOVARTIS INTERNATIONAL AG
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Business performance
9.5.5. Key strategic moves and developments
9.6. ABBOTT LABORATORIES
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance
9.6.5. Key strategic moves and developments
9.7. BAYER AG
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments
9.8. SCYNEXIS INC.
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance
9.8.5. Key strategic moves and developments
9.9. ENZON PHARMACEUTICALS INC.
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Business performance
9.9.5. Key strategic moves and developments
9.10. GLAXOSMITHKLINE PLC
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Business performance
9.10.5. Key strategic moves and developments
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.1.1. Increasing prevalence of fungal infection
3.6.1.2. Rising awareness levels pertaining to myriad fungal infections
3.6.1.3. Favorable government funds to combat the antifungal diseases
3.6.2. Restraints
3.6.2.1. Growing population with antifungal drug resistance
3.6.2.2. Presence of counterfeit drugs and side effects of antifungal drugs
3.6.3. Opportunities
3.6.3.1. Patent expirations and increasing funding from public & private organizations
CHAPTER 4 ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. SUPERFICIAL ANTIFUNGAL INFECTION
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. SYSTEMIC ANTIFUNGAL INFECTION
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
CHAPTER 5 ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. ECHINOCANDINS
5.2.1. Market size and forecast
5.2.2. Micafungin
5.2.2.1. Market size and forecast
5.2.3. Caspofungin
5.2.3.1. Market size and forecast
5.2.4. Anidulafungin
5.2.4.1. Market size and forecast
5.2.5. Others
5.2.5.1. Market size and forecast
5.3. AZOLES
5.3.1. Market size and forecast
5.3.1. Imidazoles
5.3.1.1. Market size and forecast
5.3.2. Voricanazole
5.3.2.1. Market size and forecast
5.3.3. Thiazoles
5.3.3.1. Market size and forecast
5.3.4. Others
5.3.4.1. Market size and forecast
5.4. POLYENES
5.4.1. Market size and forecast
5.4.2. Amphotericin B
5.4.2.1. Market size and forecast
5.4.3. Candicidin
5.4.3.1. Market size and forecast
5.4.4. Hamycin
5.4.4.1. Market size and forecast
5.4.5. Natamycin
5.4.5.1. Market size and forecast
5.4.6. Others
5.4.6.1. Market size and forecast
5.5. ALLYLAMINES
5.5.1. Market size and forecast
5.5.1. Terbinafine
5.5.1.1. Market size and forecast
5.5.2. Butenafine
5.5.2.1. Market size and forecast
5.5.3. Naftifine
5.5.3.1. Market size and forecast
5.6. OTHERS
5.6.1. Market size and forecast
CHAPTER 6 ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. ASPERGILLOSIS
6.2.1. Market size and forecast
6.3. DERMATOPHYTOSIS
6.3.1. Market size and forecast
6.4. CANDIDIASIS
6.4.1. Market size and forecast
6.5. OTHERS
6.5.1. Market size and forecast
CHAPTER 7 ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. POWDER
7.2.1. Market size and forecast
7.3. OINTMENTS
7.3.1. Market size and forecast
7.4. DRUGS
7.4.1. Market size and forecast
7.5. OTHERS
7.5.1. Market size and forecast
CHAPTER 8 ANTIFUNGAL DRUGS MARKET, BY GEOGRAPHY
8.1. OVERVIEW
8.1.1. Market size and forecast
8.2. NORTH AMERICA
8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast
8.2.3.1. U.S. market size and forecast
8.2.3.2. Mexico market size and forecast
8.2.3.3. Canada market size and forecast
8.3. EUROPE
8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast
8.3.3.1. UK market size and forecast
8.3.3.2. France market size and forecast
8.3.3.3. Germany market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Spain market size and forecast
8.3.3.6. Rest of Europe market size and forecast
8.4. ASIA-PACIFIC
8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast
8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. India market size and forecast
8.4.3.4. Australia market size and forecast
8.4.3.5. Rest of Asia-Pacific market size and forecast
8.5. LAMEA
8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast
8.5.3.1. Brazil market size and forecast
8.5.3.2. Argentina market size and forecast
8.5.3.3. Saudi Arabia market size and forecast
8.5.3.4. South Africa market size and forecast
8.5.3.5. Rest of LAMEA market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1. PFIZER INC.
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance
9.1.5. Key strategic moves and developments
9.2. SANOFI S.A
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Business performance
9.2.5. Key strategic moves and developments
9.3. GILEAD SCIENCES INC.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Business performance
9.3.5. Key strategic moves and developments
9.4. MERCK & CO., INC.
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance
9.4.5. Key strategic moves and developments
9.5. NOVARTIS INTERNATIONAL AG
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Business performance
9.5.5. Key strategic moves and developments
9.6. ABBOTT LABORATORIES
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance
9.6.5. Key strategic moves and developments
9.7. BAYER AG
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments
9.8. SCYNEXIS INC.
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance
9.8.5. Key strategic moves and developments
9.9. ENZON PHARMACEUTICALS INC.
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Business performance
9.9.5. Key strategic moves and developments
9.10. GLAXOSMITHKLINE PLC
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Business performance
9.10.5. Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 2. GLOBAL SUPERFICIAL ANTIFUNGAL INFECTION MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 3. GLOBAL SYSTEMIC ANTIFUNGAL INFECTION MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 5. GLOBAL ANTIFUNGAL DRUGS MARKET FOR ECHINOCANDINS, BY TYPE, 2016-2023 ($MILLION)
TABLE 6. GLOBAL ANTIFUNGAL DRUGS MARKET FOR ECHINOCANDINS, BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR MICAFUNGIN, BY REGION, 2016-2023 ($MILLION)
TABLE 8. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR CASPOFUNGIN, BY REGION, 2016-2023 ($MILLION)
TABLE 9. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR ANIDULAFUNGIN, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR OTHER DRUGS, BY REGION, 2016-2023 ($MILLION)
TABLE 11. GLOBAL ANTIFUNGAL DRUGS MARKET FOR AZOLES, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 12. GLOBAL ANTIFUNGAL DRUGS MARKET FOR AZOLES, BY REGION, 2016-2023 ($MILLION)
TABLE 13. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR IMIDAZOLES, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR VORICANAZOLE, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR THIAZOLES, BY REGION, 2016-2023 ($MILLION)
TABLE 16. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR OTHER DRUGS, BY REGION, 2016-2023 ($MILLION)
TABLE 17. GLOBAL ANTIFUNGAL DRUGS MARKET FOR POLYENES, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 18. GLOBAL ANTIFUNGAL DRUGS MARKET FOR POLYENES, BY REGION, 2016-2023 ($MILLION)
TABLE 19. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR AMPHOTERICIN B, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR CANDICIDIN, BY REGION, 2016-2023 ($MILLION)
TABLE 21. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR HAMYCIN, BY REGION, 2016-2023 ($MILLION)
TABLE 22. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR NATAMYCIN, BY REGION, 2016-2023 ($MILLION)
TABLE 23. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR OTHER DRUGS, BY REGION, 2016-2023 ($MILLION)
TABLE 24. GLOBAL ANTIFUNGAL DRUGS FOR ALLYLAMINES MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 25. GLOBAL ANTIFUNGAL DRUGS FOR ALLYLAMINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 26. GLOBAL ALLYLAMINES ANTIFUNGAL DRUGS MARKET FOR TERBINAFINE, BY REGION, 2016-2023 ($MILLION)
TABLE 27. GLOBAL ALLYLAMINES ANTIFUNGAL DRUGS MARKET FOR BUTENAFINE, BY REGION, 2016-2023 ($MILLION)
TABLE 28. GLOBAL ALLYLAMINES ANTIFUNGAL DRUGS MARKET FOR NAFTIFINE, BY REGION, 2016-2023 ($MILLION)
TABLE 29. GLOBAL ANTIFUNGAL DRUGS MARKET FOR OTHER, BY REGION, 2016-2023 ($MILLION)
TABLE 30. GLOBAL ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS, 2016-2023 ($MILLION)
TABLE 31. GLOBAL ANTIFUNGAL DRUGS MARKET FOR ASPERGILLOSIS, BY REGION, 2016-2023 ($MILLION)
TABLE 32. GLOBAL ANTIFUNGAL DRUGS MARKET FOR DERMATOPHYTOSIS, BY REGION, 2016-2023 ($MILLION)
TABLE 33. GLOBAL ANTIFUNGAL DRUGS MARKET FOR CANDIDIASIS, BY REGION, 2016-2023 ($MILLION)
TABLE 34. GLOBAL ANTIFUNGAL DRUGS MARKET FOR THERAPEUTIC INDICATIONS BY REGION, 2016-2023 ($MILLION)
TABLE 35. GLOBAL ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 36. GLOBAL ANTIFUNGAL DRUGS MARKET FOR POWDER, BY REGION, 2016-2023 ($MILLION)
TABLE 37. GLOBAL ANTIFUNGAL DRUGS MARKET FOR OINTMENTS, BY REGION, 2016-2023 ($MILLION)
TABLE 38. GLOBAL ANTIFUNGAL DRUS MARKET FOR DRUGS, BY REGION, 2016-2023 ($MILLION)
TABLE 39. GLOBAL ANTIFUNGAL DRUGS MARKET FOR OTHER DOSAGE FORMS, BY REGION, 2016-2023 ($MILLION)
TABLE 40. GLOBAL ANTIFUNGAL DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 41. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 42. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 43. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 44. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
TABLE 45. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 46. EUROPE ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 47. EUROPE ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 48. EUROPE ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 49. EUROPE ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
TABLE 50. EUROPE ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 51. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 52. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 53. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 54. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
TABLE 55. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 56. LAMEA ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 57. LAMEA ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 58. LAMEA ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 59. LAMEA ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
TABLE 60. LAMEA ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 61. PFIZER: COMPANY SNAPSHOT
TABLE 62. PFIZER: OPERATING SEGMENTS
TABLE 63. SANOFI: COMPANY SNAPSHOT
TABLE 64. SANOFI: OPERATING SEGMENTS
TABLE 65. GILEAD: COMPANY SNAPSHOT
TABLE 66. GILEAD: OPERATING SEGMENTS
TABLE 67. MERCK: COMPANY SNAPSHOT
TABLE 68. MERCK: OPERATING SEGMENTS
TABLE 69. NOVARTIS: COMPANY SNAPSHOT
TABLE 70. NOVARTIS: OPERATING SEGMENTS
TABLE 71. ABBOTT: COMPANY SNAPSHOT
TABLE 72. ABBOTT: OPERATING SEGMENTS
TABLE 73. BAYER: COMPANY SNAPSHOT
TABLE 74. BAYER: OPERATING SEGMENTS
TABLE 75. SCYNEXIS: COMPANY SNAPSHOT
TABLE 76. SCYNEXIS: OPERATING SEGMENTS
TABLE 77. ENZON: COMPANY SNAPSHOT
TABLE 78. ENZON: OPERATING SEGMENTS
TABLE 79. GSK: COMPANY SNAPSHOT
TABLE 80. GSK: OPERATING SEGMENTS
TABLE 1. GLOBAL ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 2. GLOBAL SUPERFICIAL ANTIFUNGAL INFECTION MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 3. GLOBAL SYSTEMIC ANTIFUNGAL INFECTION MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 5. GLOBAL ANTIFUNGAL DRUGS MARKET FOR ECHINOCANDINS, BY TYPE, 2016-2023 ($MILLION)
TABLE 6. GLOBAL ANTIFUNGAL DRUGS MARKET FOR ECHINOCANDINS, BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR MICAFUNGIN, BY REGION, 2016-2023 ($MILLION)
TABLE 8. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR CASPOFUNGIN, BY REGION, 2016-2023 ($MILLION)
TABLE 9. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR ANIDULAFUNGIN, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR OTHER DRUGS, BY REGION, 2016-2023 ($MILLION)
TABLE 11. GLOBAL ANTIFUNGAL DRUGS MARKET FOR AZOLES, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 12. GLOBAL ANTIFUNGAL DRUGS MARKET FOR AZOLES, BY REGION, 2016-2023 ($MILLION)
TABLE 13. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR IMIDAZOLES, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR VORICANAZOLE, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR THIAZOLES, BY REGION, 2016-2023 ($MILLION)
TABLE 16. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR OTHER DRUGS, BY REGION, 2016-2023 ($MILLION)
TABLE 17. GLOBAL ANTIFUNGAL DRUGS MARKET FOR POLYENES, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 18. GLOBAL ANTIFUNGAL DRUGS MARKET FOR POLYENES, BY REGION, 2016-2023 ($MILLION)
TABLE 19. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR AMPHOTERICIN B, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR CANDICIDIN, BY REGION, 2016-2023 ($MILLION)
TABLE 21. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR HAMYCIN, BY REGION, 2016-2023 ($MILLION)
TABLE 22. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR NATAMYCIN, BY REGION, 2016-2023 ($MILLION)
TABLE 23. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR OTHER DRUGS, BY REGION, 2016-2023 ($MILLION)
TABLE 24. GLOBAL ANTIFUNGAL DRUGS FOR ALLYLAMINES MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 25. GLOBAL ANTIFUNGAL DRUGS FOR ALLYLAMINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 26. GLOBAL ALLYLAMINES ANTIFUNGAL DRUGS MARKET FOR TERBINAFINE, BY REGION, 2016-2023 ($MILLION)
TABLE 27. GLOBAL ALLYLAMINES ANTIFUNGAL DRUGS MARKET FOR BUTENAFINE, BY REGION, 2016-2023 ($MILLION)
TABLE 28. GLOBAL ALLYLAMINES ANTIFUNGAL DRUGS MARKET FOR NAFTIFINE, BY REGION, 2016-2023 ($MILLION)
TABLE 29. GLOBAL ANTIFUNGAL DRUGS MARKET FOR OTHER, BY REGION, 2016-2023 ($MILLION)
TABLE 30. GLOBAL ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS, 2016-2023 ($MILLION)
TABLE 31. GLOBAL ANTIFUNGAL DRUGS MARKET FOR ASPERGILLOSIS, BY REGION, 2016-2023 ($MILLION)
TABLE 32. GLOBAL ANTIFUNGAL DRUGS MARKET FOR DERMATOPHYTOSIS, BY REGION, 2016-2023 ($MILLION)
TABLE 33. GLOBAL ANTIFUNGAL DRUGS MARKET FOR CANDIDIASIS, BY REGION, 2016-2023 ($MILLION)
TABLE 34. GLOBAL ANTIFUNGAL DRUGS MARKET FOR THERAPEUTIC INDICATIONS BY REGION, 2016-2023 ($MILLION)
TABLE 35. GLOBAL ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 36. GLOBAL ANTIFUNGAL DRUGS MARKET FOR POWDER, BY REGION, 2016-2023 ($MILLION)
TABLE 37. GLOBAL ANTIFUNGAL DRUGS MARKET FOR OINTMENTS, BY REGION, 2016-2023 ($MILLION)
TABLE 38. GLOBAL ANTIFUNGAL DRUS MARKET FOR DRUGS, BY REGION, 2016-2023 ($MILLION)
TABLE 39. GLOBAL ANTIFUNGAL DRUGS MARKET FOR OTHER DOSAGE FORMS, BY REGION, 2016-2023 ($MILLION)
TABLE 40. GLOBAL ANTIFUNGAL DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 41. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 42. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 43. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 44. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
TABLE 45. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 46. EUROPE ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 47. EUROPE ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 48. EUROPE ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 49. EUROPE ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
TABLE 50. EUROPE ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 51. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 52. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 53. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 54. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
TABLE 55. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 56. LAMEA ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 57. LAMEA ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 58. LAMEA ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 59. LAMEA ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
TABLE 60. LAMEA ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 61. PFIZER: COMPANY SNAPSHOT
TABLE 62. PFIZER: OPERATING SEGMENTS
TABLE 63. SANOFI: COMPANY SNAPSHOT
TABLE 64. SANOFI: OPERATING SEGMENTS
TABLE 65. GILEAD: COMPANY SNAPSHOT
TABLE 66. GILEAD: OPERATING SEGMENTS
TABLE 67. MERCK: COMPANY SNAPSHOT
TABLE 68. MERCK: OPERATING SEGMENTS
TABLE 69. NOVARTIS: COMPANY SNAPSHOT
TABLE 70. NOVARTIS: OPERATING SEGMENTS
TABLE 71. ABBOTT: COMPANY SNAPSHOT
TABLE 72. ABBOTT: OPERATING SEGMENTS
TABLE 73. BAYER: COMPANY SNAPSHOT
TABLE 74. BAYER: OPERATING SEGMENTS
TABLE 75. SCYNEXIS: COMPANY SNAPSHOT
TABLE 76. SCYNEXIS: OPERATING SEGMENTS
TABLE 77. ENZON: COMPANY SNAPSHOT
TABLE 78. ENZON: OPERATING SEGMENTS
TABLE 79. GSK: COMPANY SNAPSHOT
TABLE 80. GSK: OPERATING SEGMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL ANTIFUNGAL DRUGS MARKET, 2016-2023
FIGURE 2. SEGMENTATION OF ANTIFUNGAL DRUGS MARKET
FIGURE 3. TOP INVESTMENT POCKETS IN GLOBAL ANTIFUNGAL DRUGS MARKET
FIGURE 4. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2017)
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 6. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 7. BARGAINING POWER OF BUYERS
FIGURE 8. BARGAINING POWER OF SUPPLIERS
FIGURE 9. THREAT OF NEW ENTRANTS
FIGURE 10. THREAT OF SUBSTITUTION
FIGURE 11. COMPETITIVE RIVALRY
FIGURE 12. RESTRAINTS AND DRIVERS: GLOBAL ANTIFUNGAL DRUGS MARKET
FIGURE 13. U.S. ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 14. MEXICO ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 15. CANADA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 16. UK ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 17. FRANCE ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 18. GERMANY ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 19. ITALY ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 20. SPAIN ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 21. REST OF EUROPE ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 22. JAPAN ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 23. CHINA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 24. INDIA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 25. AUSTRALIA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 26. REST OF ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 27. BRAZIL ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 28. ARGENTINA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 29. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 30. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 31. REST OF LAMEA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 32. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. PFIZER: REVENUE BY SEGMENT, 2016 (%)
FIGURE 34. PFIZER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 35. SANOFI: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. SANOFI: REVENUE BY SEGMENT, 2016 (%)
FIGURE 37. SANOFI: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 38. GILEAD: NET SALES, 2014-2016 ($MILLION)
FIGURE 39. GILEAD: REVENUE BY SEGMENT, 2016 (%)
FIGURE 40. GILEAD: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 41. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 42. MERCK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 43. MERCK: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 44. NOVARTIS: NET SALES, 2014-2016 ($MILLION)
FIGURE 45. NOVARTIS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 46. NOVARTIS: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 47. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 48. ABBOTT: REVENUE BY SEGMENT, 2016 (%)
FIGURE 49. ABBOTT: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 50. BAYER: NET SALES, 2014-2016 ($MILLION)
FIGURE 51. BAYER: REVENUE BY SEGMENT, 2016 (%)
FIGURE 52. BAYER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 53. SCYNEXIS: NET SALES, 2014-2016 ($MILLION)
FIGURE 54. SCYNEXIS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 55. SCYNEXIS: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 56. ENZON: NET SALES, 2014-2016 ($MILLION)
FIGURE 57. ENZON: REVENUE BY SEGMENT, 2016 (%)
FIGURE 58. ENZON: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 59. GSK: NET SALES, 2014-2016 ($MILLION)
FIGURE 60. GSK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 61. GSK: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 1. GLOBAL ANTIFUNGAL DRUGS MARKET, 2016-2023
FIGURE 2. SEGMENTATION OF ANTIFUNGAL DRUGS MARKET
FIGURE 3. TOP INVESTMENT POCKETS IN GLOBAL ANTIFUNGAL DRUGS MARKET
FIGURE 4. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2017)
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 6. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 7. BARGAINING POWER OF BUYERS
FIGURE 8. BARGAINING POWER OF SUPPLIERS
FIGURE 9. THREAT OF NEW ENTRANTS
FIGURE 10. THREAT OF SUBSTITUTION
FIGURE 11. COMPETITIVE RIVALRY
FIGURE 12. RESTRAINTS AND DRIVERS: GLOBAL ANTIFUNGAL DRUGS MARKET
FIGURE 13. U.S. ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 14. MEXICO ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 15. CANADA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 16. UK ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 17. FRANCE ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 18. GERMANY ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 19. ITALY ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 20. SPAIN ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 21. REST OF EUROPE ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 22. JAPAN ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 23. CHINA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 24. INDIA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 25. AUSTRALIA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 26. REST OF ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 27. BRAZIL ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 28. ARGENTINA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 29. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 30. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 31. REST OF LAMEA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 32. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. PFIZER: REVENUE BY SEGMENT, 2016 (%)
FIGURE 34. PFIZER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 35. SANOFI: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. SANOFI: REVENUE BY SEGMENT, 2016 (%)
FIGURE 37. SANOFI: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 38. GILEAD: NET SALES, 2014-2016 ($MILLION)
FIGURE 39. GILEAD: REVENUE BY SEGMENT, 2016 (%)
FIGURE 40. GILEAD: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 41. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 42. MERCK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 43. MERCK: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 44. NOVARTIS: NET SALES, 2014-2016 ($MILLION)
FIGURE 45. NOVARTIS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 46. NOVARTIS: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 47. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 48. ABBOTT: REVENUE BY SEGMENT, 2016 (%)
FIGURE 49. ABBOTT: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 50. BAYER: NET SALES, 2014-2016 ($MILLION)
FIGURE 51. BAYER: REVENUE BY SEGMENT, 2016 (%)
FIGURE 52. BAYER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 53. SCYNEXIS: NET SALES, 2014-2016 ($MILLION)
FIGURE 54. SCYNEXIS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 55. SCYNEXIS: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 56. ENZON: NET SALES, 2014-2016 ($MILLION)
FIGURE 57. ENZON: REVENUE BY SEGMENT, 2016 (%)
FIGURE 58. ENZON: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 59. GSK: NET SALES, 2014-2016 ($MILLION)
FIGURE 60. GSK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 61. GSK: REVENUE BY GEOGRAPHY, 2016 (%)
